Outsourced healthcare services provider Ashfield, part of UDG Healthcare, has announced the launch of an agile, multi-channel engagement model underpinned by a field analytics engine to address the challenges of pharmaceutical companies needing to maintain or improve return on investment (ROI). Utilizing the AshfieldGuide, a sales analytics and planning platform, The Ashfield Solution is said to provide a more efficient, impactful and agile sales model with the capability to flex resources in "real-time" in reaction to market events.
The new model helps pharmaceutical companies optimize their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars. It reportedly provides advanced analytics capabilities in response to curve modeling, segmentation techniques, mix modeling and geospatial optimization. In addition, the commercial model delivers engagement optimization and monthly reporting on ROI, call attainment and performance.
For more information, visit www.ashfieldhealthcare.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.